NasdaqCM - Delayed Quote • USD
Veru Inc. (VERU)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:09 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 3 | 3 | 3 | 2 |
Avg. Estimate | -0.06 | -0.06 | -0.26 | -0.3 |
Low Estimate | -0.07 | -0.07 | -0.29 | -0.32 |
High Estimate | -0.04 | -0.05 | -0.21 | -0.29 |
Year Ago EPS | -0.48 | 0.07 | -1.1 | -0.26 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 3 | 3 | 3 | 2 |
Avg. Estimate | 3.33M | 3.03M | 11.37M | 9M |
Low Estimate | 2M | 2M | 8.1M | 8M |
High Estimate | 4M | 4.1M | 14.4M | 10M |
Year Ago Sales | -- | -- | 16.3M | 11.37M |
Sales Growth (year/est) | -- | -- | -30.20% | -20.80% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.33 | -0.2 | -0.23 | -0.1 |
EPS Actual | -0.48 | 0.07 | -0.12 | -0.08 |
Difference | -0.15 | 0.27 | 0.11 | 0.02 |
Surprise % | -45.50% | 135.00% | 47.80% | 20.00% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.06 | -0.06 | -0.26 | -0.3 |
7 Days Ago | -0.06 | -0.06 | -0.26 | -0.3 |
30 Days Ago | -0.08 | -0.07 | -0.32 | -0.34 |
60 Days Ago | -0.1 | -0.08 | -0.37 | -0.39 |
90 Days Ago | -0.11 | -0.09 | -0.42 | -0.39 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | 1 | 1 | 1 | 1 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | VERU | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 87.50% | -- | -- | 5.40% |
Next Qtr. | -185.70% | -- | -- | 10.90% |
Current Year | 76.40% | -- | -- | 4.50% |
Next Year | -15.40% | -- | -- | 13.10% |
Next 5 Years (per annum) | 127.60% | -- | -- | 10.94% |
Past 5 Years (per annum) | -61.15% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | Oppenheimer: Outperform to Outperform | 4/15/2024 |
Initiated | Raymond James: Outperform | 3/28/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 2/8/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 9/27/2023 |
Upgrade | Jefferies: Underperform to Hold | 6/7/2023 |
Maintains | HC Wainwright & Co.: Buy to Buy | 5/15/2023 |
Related Tickers
NKGN NKGen Biotech, Inc.
1.6100
-18.69%
JAGX Jaguar Health, Inc.
0.1800
+5.88%
CADL Candel Therapeutics, Inc.
6.39
-0.62%
ANVS Annovis Bio, Inc.
18.01
+32.43%
OCGN Ocugen, Inc.
1.2800
+8.47%
EYEN Eyenovia, Inc.
0.6282
-11.68%
TVGN Tevogen Bio Holdings Inc.
1.0000
+17.65%
GLSI Greenwich LifeSciences, Inc.
13.12
+6.32%
VNDA Vanda Pharmaceuticals Inc.
4.6200
+3.12%
SLS SELLAS Life Sciences Group, Inc.
1.4600
-3.95%